Archive for 2008/01


N30 Pharma Announces Successful Initiation Of Human Studies With N30-201

N30 Pharma (N30), a biopharmaceutical company focused on the discovery, development, and commercialization of respiratory drugs that target endogenous s-nitrosothiols, announced that it has successfully completed Phase 1 study of N30-201 in healthy volunteers. N30 intends to develop N30-201 for the treatment of reactive and obstructive airway diseases, including Cystic Fibrosis and asthma.
(more...)


01/29/2008 | Respiratory & Asthma | Trackback | Comments Off

Common Human Viruses Threaten Endangered Great Apes

Common human viruses are responsible for outbreaks of respiratory disease that have led to the decline of endangered chimpanzees in the wild, according to a study reported online on January 24th in Current Biology, a publication of Cell Press.
(more...)


01/28/2008 | Respiratory & Asthma | Trackback | Comments Off

ImaRx Therapeutics Receives Urokinase Lot Release Approval With Extended Expiration Dating

ImaRx Therapeutics, Inc. (Nasdaq: IMRX) announced that the Food and Drug Administration (FDA) has approved the company's most current lot release request for urokinase drug product. This is the first lot to be released with extended expiration dating. Urokinase, ImaRx's first commercially available FDA-approved product, is a thrombolytic or clot-dissolving agent indicated for the treatment of acute massive pulmonary embolism.
(more...)


01/26/2008 | Respiratory & Asthma | Trackback | Comments Off

Alnylam Reports Positive Phase II Data For ALN-RSV01, An RNAi Therapeutic For The Treatment Of Respiratory Syncytial Virus (RSV) Infection

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), a leading RNAi therapeutics company, reported positive data for the ALN-RSV01 Phase II experimental infection study, now called "GEMINI." The GEMINI study was designed to evaluate the safety and anti-viral activity of ALN-RSV01, an RNAi therapeutic for the treatment of RSV infection. Top-line results show that ALN-RSV01 was safe and well tolerated and demonstrated statistically significant anti-viral activity.
(more...)


01/25/2008 | Respiratory & Asthma | Trackback | Comments Off

Vitamin E Linked To Physical Activity

Only one person in the study took vitamin E supplements Vitamin E "helps older people move" is the headline in The Daily Telegraph. The newspaper report underneath says that "a diet rich in olive oil, nuts and green leafy vegetables could help slow physical decline in the elderly".
(more...)


01/25/2008 | Complememntary & Alternative Medicine | Trackback | Comments Off

Taro Receives FDA Approval Of New Drug Application For Flo-Pred(TM) (Prednisolone Acetate Oral Suspension)

Taro Pharmaceutical Industries Ltd. (the "Company" or "Taro," Pink Sheets: TAROF) reported that its U.S. affiliate, Taro Pharmaceuticals U.S.A., Inc. ("Taro USA") has received approval from the U.S. Food and Drug Administration for its New Drug Application (NDA) for Flo-PredTM (prednisolone acetate oral suspension) equivalent to 5 mg/5 mL and 15 mg/5 mL prednisolone in Taro's patent-protected NonSpilTM liquid drug delivery system.
(more...)


01/25/2008 | Respiratory & Asthma | Trackback | Comments Off

President Rodriguez Issues Charge To Respiratory Therapists To Gear Up For Legislative Passage Of The Respiratory Therapy Initiative, USA

President Toni Rodriguez charged all respiratory therapists to jump the last major hurdle in solidifying the identity of Respiratory Care as a profession at the December annual meeting of the AARC. "On our 60th anniversary we stand on the brink of some of our greatest accomplishments as a profession," says President Rodriguez. "When the right time and the right circumstances fuse, you must be ready to act." Dr.
(more...)


01/24/2008 | Respiratory & Asthma | Trackback | Comments Off

Marijuana Smokers Face Rapid Lung Destruction - As Much As 20 Years Ahead Of Tobacco Smokers

A study in a Wiley-Blackwell journal - Respirology - finds that the development of bullous lung disease occurs in marijuana smokers approximately 20 years earlier than tobacco smokers. A condition often caused by exposure to toxic chemicals or long-term exposure to tobacco smoke, bullous lung disease (also known as bullae) is a condition where air trapped in the lungs causes obstruction to breathing and eventual destruction of the lungs.
(more...)


01/24/2008 | Respiratory & Asthma | Trackback | Comments Off

Future Patients Could Be Breathing Easier After Results Of Novel Ventilator Study

An animal study published in the February 2008 issue of Anesthesiology has found that inhibiting specific enzymes during mechanical ventilation of the lungs reduces the amount of potential damage to the lungs and even helps to protect the kidneys.According to Arthur S. Slutsky, M.D., a critical care specialist at St.
(more...)


01/24/2008 | Respiratory & Asthma | Trackback | Comments Off

Our Kids Deserve It: Lung Association Launches National Push For Smoke-free Cars, Canada

The Lung Association launched "Stop Smoking in Cars! Our Kids Deserve It!" - a nationwide campaign designed to help Canadians push their provincial governments to tackle the issue of smoking in cars where children are present. The Association wants provincial governments to ensure people "butt out" if they are driving with kids. Canadians are urged to visit http://www.cleanairforkids.
(more...)


01/23/2008 | Respiratory & Asthma | Trackback | Comments Off

« Previous Entries
Next Entries »

© 2006 MBGJ.Org Limited Trading as Natural-Remedies-Clinic

All rights reserved - Designated trademarks and brands are the property of their respective owners

Natural Remedies Clinic - Main Site


Page Sponsors

Implant Dangers -Hypothyroidism Weight Gain -Medical Weight Loss Center

>-- Top of Page --<